Evidence map›Paper›PMID 39825941›Full record

ArticleArchives of dermatological research2025

Evaluation of the serum level of Lipocalin 2 in vitiligo.

Marwa A Nassar, Douaa S Alsaadany, Olfat G Shaker, Talal A Abd El-Raheem

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marwa A NassarDepartment of Dermatology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Douaa S AlsaadanyAl-Haud Al-Marsaud Hospital for Dermatology, Venereology and Andrology, Cairo, Egypt.
Olfat G ShakerDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt. olfat.shaker@kasralainy.edu.eg.
Talal A Abd El-RaheemDepartment of Dermatology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is considered as depigmenting skin disorder where patches of skin losing their pigment. Lipocalin-2 (LCN2) is one of the Inflammatory adipokines that has a potential role in skin disorders and other inflammatory diseases as well. To measure the concentration level of LCN2 in vitiligo patients compared to healthy controls and to investigate its relation to disease activity and other clinical data to evaluate its role in the pathogenesis of the disease. Eighty individuals subdivided equally into two groups (vitiligo and controls) were enrolled in the study. The serum level of LCN2 was measured by ELISA where from all participants, a 5-mL venous blood was withdrawn in plain tube from each subject. There were high significant difference of LCN2 in serum between both groups where LCN2 was higher in vitiligo patients than than controls with mean and standard deviations of 399.2 ± 134.6 and 257.2 ± 42.5 respectively (p < 0.001). The level of LCN2 tended to increase in vitiligo patients with sudden onset than gradual patients showing a significant difference with p-value 0.030. Regarding the severity of the disease results showed that the level of LCN2 tended to increase in moderate and severe patients than mild but with no significant difference between the groups. LCN2 may play a vital role and a good marker for the early diagnosis and the pathogenesis of vitiligo disease.

Indexed as

Lipocalin-2VitiligoAdolescentAdultBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedSeverity of Illness IndexYoung AdultBiomarkersLCN2 protein, humanLipocalin-2Lipocalin-2VASIVIDAVitiligo

Identifiers

PMID39825941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.